Valeant Pharmaceuticals, which also owns Bausch & Lomb here, is selling its Dendreon cancer business and three skincare brands for about $2.12bn (€2bn) as the troubled Canadian drugmaker looks to pay down its more than $30bn (€28.5bn) debt.